The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and is pushing higher. At the time of writing, the benchmark index is up 1.1% to 7,728.6 points.
Four ASX shares that are rising more than most today are listed below. Here's why they are storming higher:
Image source: Getty Images
DroneShield Ltd (ASX: DRO)
The DroneShield share price is up 12% to $1.00. Investors have been buying this counter drone technology company's shares following the announcement of new contract wins. Droneshield revealed that it has received a package of five separate contracts totalling $32.2 million. These contracts were placed by an in-country reseller for delivery to a military end customer in an Asian Pacific country. Commenting on the news, Droneshield CEO, Oleg Vornik, said: "In close succession to the earlier order announced on 29 January 2025 from this sophisticated customer and a close military ally of Australia in the Asia Pacific region, DroneShield products are again meeting the challenge set by them. The scale and frequency of orders has been increasing as leading counter-drone customers are moving from testing hardware to broader roll-outs. DroneShield is rapidly expanding all aspects of the business to meet this demand across multiple regions."
Fiducian Group Ltd (ASX: FID)
The Fiducian share price is up 5.5% to $8.97. This follows the release of the financial services company's third quarter update. The company revealed that net inflows to the core Fiducian platform from aligned dealer-group for the quarter ending 31 March 2025 were $59 million and year to date $245 million. It also advised that its badged platform and Auxilium fund balance was $182 million and the net inflows for the quarter ending 31 March 2025 were $40 million.
Neuren Pharmaceuticals Ltd (ASX: NEU)
The Neuren Pharmaceuticals share price is up 20% to $10.98. This morning, this pharmaceutical company revealed that the upcoming Phase 3 trial for NNZ-2591, a potential treatment for Phelan-McDermid syndrome (PMS), has received the green light from the US FDA to proceed as planned. The company's CEO, Jon Pilcher, commented: "We are very pleased with the outcome of another constructive discussion with the FDA and are now excited to be able to move forward as planned with the first ever Phase 3 trial in children with Phelan-McDermid syndrome."
Newmont Corporation (ASX: NEM)
The Newmont share price is up 4% to $86.84. Investors have been buying this gold miner's shares following another strong rise by the precious metal on Friday. It isn't just Newmont shares that are rising today. Most gold miners are pushing higher, which has led to the S&P/ASX All Ordinaries Gold index climbing 1.3% at the time of writing.
